- Is The Mark Foundation for Cancer Research US a tax-exempt 501(c)(3)?
- Yes. The Mark Foundation for Cancer Research US is recognised by the IRS as a 501(c)(3) organisation (EIN 36-4825921). The IRS recognised The Mark Foundation for Cancer Research US as tax-exempt in August 2016.
- What is The Mark Foundation for Cancer Research US's EIN?
- The Mark Foundation for Cancer Research US's Employer Identification Number (EIN) is 36-4825921. The EIN was assigned by the IRS in August 2016. Donors and grantmakers use the EIN to verify tax-exempt status with the IRS.
- What does The Mark Foundation for Cancer Research US do?
- Accelerate research to transform prevention, diagnosis and treatment of cancer.
- Where is The Mark Foundation for Cancer Research US located?
- The Mark Foundation for Cancer Research US is located at 1350 Avenue of the Americas 2902, New York, NY, 10019.
- When was The Mark Foundation for Cancer Research US founded or recognised by the IRS?
- The Mark Foundation for Cancer Research US was recognised by the IRS as a tax-exempt organisation in August 2016. The IRS ruling date is the earliest authoritative date available for most US nonprofits.
- What is The Mark Foundation for Cancer Research US's annual revenue?
- On its most recent Form 990 (fiscal year 2024), The Mark Foundation for Cancer Research US reported $44.8M in total revenue and $36.1M in total expenses.
- Has The Mark Foundation for Cancer Research US been auto-revoked by the IRS?
- No. The Mark Foundation for Cancer Research US (EIN 36-4825921) does not appear on the IRS Auto-Revocation List. Givalgo Discover cross-references the IRS Auto-Revocation List on every profile load; if status changes, this page reflects it.
- Is The Mark Foundation for Cancer Research US listed in IRS Publication 78?
- Yes. The Mark Foundation for Cancer Research US is listed in IRS Publication 78 as an organisation eligible to receive tax-deductible charitable contributions. Pub 78 status is the canonical IRS signal that donations to an org are deductible.
